Lantheus (NASDAQ:LNTH) Price Target Cut to $112.00 by Analysts at JMP Securities

Lantheus (NASDAQ:LNTH - Free Report) had its price target lowered by JMP Securities from $125.00 to $112.00 in a research note released on Thursday,Benzinga reports. The brokerage currently has a market outperform rating on the medical equipment provider's stock.

LNTH has been the subject of several other research reports. Redburn Atlantic assumed coverage on shares of Lantheus in a research report on Tuesday, September 3rd. They set a "buy" rating and a $175.00 price target for the company. B. Riley boosted their price target on Lantheus from $105.00 to $146.00 and gave the stock a "buy" rating in a research note on Thursday, July 25th. Leerink Partners upped their price target on Lantheus from $106.00 to $127.00 and gave the company an "outperform" rating in a report on Thursday, July 11th. Finally, Truist Financial reduced their price objective on Lantheus from $141.00 to $135.00 and set a "buy" rating for the company in a report on Thursday, August 1st. Two investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $124.38.

Lantheus Stock Down 3.1 %

NASDAQ LNTH traded down $2.86 during trading hours on Thursday, reaching $88.32. 2,878,409 shares of the company's stock traded hands, compared to its average volume of 990,289. Lantheus has a 52-week low of $50.20 and a 52-week high of $126.89. The company has a debt-to-equity ratio of 0.55, a current ratio of 4.68 and a quick ratio of 4.41. The firm has a 50-day simple moving average of $107.71 and a 200 day simple moving average of $95.52. The firm has a market cap of $6.13 billion, a PE ratio of 14.48 and a beta of 0.51.

Lantheus (NASDAQ:LNTH - Get Free Report) last released its earnings results on Wednesday, November 6th. The medical equipment provider reported $1.48 EPS for the quarter, topping analysts' consensus estimates of $1.40 by $0.08. Lantheus had a return on equity of 48.36% and a net margin of 29.80%. The firm had revenue of $378.73 million for the quarter, compared to analysts' expectations of $373.58 million. Sell-side analysts anticipate that Lantheus will post 5.99 EPS for the current fiscal year.

Insider Activity at Lantheus

In related news, Director Gerard Ber sold 15,500 shares of the firm's stock in a transaction on Monday, August 12th. The stock was sold at an average price of $96.48, for a total value of $1,495,440.00. Following the transaction, the director now directly owns 21,221 shares of the company's stock, valued at approximately $2,047,402.08. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 2.10% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Lantheus

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Signaturefd LLC increased its stake in shares of Lantheus by 40.5% in the third quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider's stock worth $35,000 after purchasing an additional 92 shares in the last quarter. Silverberg Bernstein Capital Management LLC boosted its holdings in Lantheus by 0.4% in the 2nd quarter. Silverberg Bernstein Capital Management LLC now owns 22,843 shares of the medical equipment provider's stock worth $1,834,000 after buying an additional 100 shares during the period. UMB Bank n.a. increased its stake in Lantheus by 42.1% in the 3rd quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider's stock worth $47,000 after buying an additional 126 shares in the last quarter. GAMMA Investing LLC raised its holdings in Lantheus by 45.5% during the third quarter. GAMMA Investing LLC now owns 467 shares of the medical equipment provider's stock valued at $51,000 after acquiring an additional 146 shares during the period. Finally, Moody National Bank Trust Division lifted its position in shares of Lantheus by 1.1% in the second quarter. Moody National Bank Trust Division now owns 14,984 shares of the medical equipment provider's stock valued at $1,203,000 after acquiring an additional 162 shares in the last quarter. Institutional investors own 99.06% of the company's stock.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.